HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glutamine Claim Class Action Against GNC Gets Wide Berth For Relevant Studies

This article was originally published in The Rose Sheet

Executive Summary

An Illinois federal judge denies GNC motion to dismiss based partly on argument that studies of products with different formulations or delivery formats than the challenged Pro Performance supplements are inappropriate as evidence for the complaint alleging consumer fraud.

You may also be interested in...



Another Court Ruling Rejects RCT Standard For Supplement Claims

Two years after Bayer prevailed against FTC's demand for RCTs to substantiate claims for its Phillips Colon Health probiotic, a judge dismisses a class action complaint targeting the product, saying the plaintiffs did not support their argument and their expert expected supplements to be evaluated as drugs.

Poor Fit For FitTea Evidence, No Free Pass For Testimonials – NAD

NAD advises Fit Products to modify FitTea claims because its formulation is not the same as studies submitted and reminds the firm that testimonials must not contain false claims about products.

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

Topics

Related Companies

UsernamePublicRestriction

Register

RS121162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel